Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neuronetics (STIM) EBITDA Margin (2017 - 2026)

Neuronetics has reported EBITDA Margin over the past 10 years, most recently at 26.11% for Q1 2026.

  • Quarterly EBITDA Margin rose 834.0% to 26.11% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 19.4% through Mar 2026, up 2389.0% year-over-year, with the annual reading at 21.08% for FY2025, 2508.0% up from the prior year.
  • EBITDA Margin was 26.11% for Q1 2026 at Neuronetics, down from 12.07% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 12.07% in Q4 2025 and troughed at 71.47% in Q1 2022.
  • The 5-year median for EBITDA Margin is 41.73% (2023), against an average of 40.78%.
  • Year-over-year, EBITDA Margin plummeted -2921bps in 2024 and then soared 3893bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 42.46% in 2022, then skyrocketed by 49bps to 21.79% in 2023, then crashed by -134bps to 51.0% in 2024, then skyrocketed by 76bps to 12.07% in 2025, then tumbled by -116bps to 26.11% in 2026.
  • Per Business Quant, the three most recent readings for STIM's EBITDA Margin are 26.11% (Q1 2026), 12.07% (Q4 2025), and 19.63% (Q3 2025).